Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Classical reporting system

Contexte Official surveillance system relies on official laws. The Lebanese Law related to communicable diseases issued on the 31st December 1957 requests from physicians and healthcare facilities to report to the MOPH selected communicable diseases.
On the other hand, the MOPH issues continuously decisions, circulars, and memos that specifies technical aspects of the national surveillance system (case definitions, forms…).
Objectives - Measure disease burden and describe the characteristics. This includes: a) Measure incidence, prevalence, and mortality rates; b) Describe event/disease by time, place and person; c) Monitor trends; d) Identify high risk populations or areas; e) Identify risk factors; f) Evaluate specific diseases control programs.
- Detect alerts and outbreaks. The detection of an outbreak gives an opportunity to investigate, find etiologies and implement corrective measures, thus aiming to reduce cases and prevent later outbreaks. Early warning and response system refers to the outbreak detection at early stages; when timely corrective measures can prevent additional new cases and stop the natural evolution of the outbreak.
Target diseases and syndromes 40 diseases and syndromes are targetted by the classical surveillance system. The diseases are displayed in 2 groups: immediate notification and weekly notification:
- The immediate notifiable diseases and syndromes are: Acute Flaccid Paralysis, Anthrax, Cholera, Diphtheria, Food Poisoning, Hemorrhagic Fever, Influenza novel viruses, Invasive Coranaviruses, Measles, Meningitis, Meningococcal infection, Mumps, Pertussis, Plague, Rabies, Rubella and Congenital Rubella Syndrome, Smallpox, Tetanus including Tetanus Neonatorum, and Unusual Event
- The weekly notifiable diseases and syndromes are: Bilharziasis, Brucellosis, Creutzfeldt-Jakob Disease (Transmissible Spongiform Encephalopathy), Gonococcal Infection,Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E, Human Immunodeficiency Virus, Human T-cell Lymphotropic Virus 1, Hydatid Disease, Intestinal Infections, Legionellosis, Leishmaniasis, Leprosy, Malaria, Syphilis, Tuberculosis, Typhoid Fever and Typhus.  
Data Sources All Physicians and Healthcare facilities
Guidelines - Communicable diseases surveillance guideline: Ar, En
- Communicable diseases surveillance standard operating procedures - part 1 (immediately notifiable diseases): En
- Communicable diseases surveillance standard operating procedures - part 2 (weekly notifiable diseases): En
Case definitions Refer to webpages "Notifiable Diseases"
Form Reporting form
Results Refer to webpage "Surveillance data"
    1
    ...
ATC Name B/G Ingredients Dosage Form Price
D10BA01 A-CNOTREN G Isotretinoin - 20mg 20mg Capsule, soft gelatin 1,526,524 L.L
D10AD01 A-RET G Tretinoin - 0.05% 0.05% Cream 335,961 L.L
N02BE51 A.B.C NIGHT G Paracetamol - 500mg, Diphenhydramine HCl - 25mg Tablet, film coated 260,152 L.L
N02BE51 A.B.C.-COLD G Paracetamol - 500mg, Chlorphenamine maleate - 4mg, Phenylephrine HCl - 5mg Tablet, film coated 534,977 L.L
B01AC06 A.S HEART G Acetylsalicylic acid - 81mg 81mg Tablet, enteric coated 148,463 L.L
N05AX12 ABILIFY MAINTENA B Aripiprazole - 400mg 400mg Injectable powder for suspension, prolonged release+solvent 29,491,998 L.L
N05AX12 ABIPREX 10 G Aripiprazole - 10mg 10mg Tablet 1,075,074 L.L
N05AX12 ABIPREX 15 G Aripiprazole - 15mg 15mg Tablet 1,075,074 L.L
L02BX03 ABIRATERONE ACETATE NEAPOLIS G Abiraterone acetate - 250mg 250mg Tablet 75,418,662 L.L
L02BX03 ABIRATERONE ACETATE SPC G Abiraterone acetate - 250mg 250mg Tablet, film coated 73,748,373 L.L
L02BX03 ABLAX 250 G Abiraterone acetate - 250mg 250mg Tablet L.L
L02BX03 ABLAX 250 G Abiraterone acetate - 250mg 250mg Tablet 45,056,853 L.L
L02BX03 ABLAX 500 G Abiraterone acetate - 500mg 500mg Tablet L.L
L02BX03 ABLAX 500 G Abiraterone acetate - 500mg 500mg Tablet 45,056,853 L.L
L01CD01 ABRAXANE BioTech Paclitaxel Albumin- bound - 5mg/ml 5mg/ml Injectable powder for dispersion 17,850,751 L.L
L02BX03 ABREMIA G Abiraterone acetate - 250mg 250mg Tablet 77,478,802 L.L
L02BX03 ABREMIA G Abiraterone acetate - 250mg 250mg Tablet L.L
L04AB04 ABRILADA BioTech Adalimumab - 40mg 40mg Injectable solution 40,259,574 L.L
L04AB04 ABRILADA BioTech Adalimumab - 40mg 40mg Injectable solution 40,259,574 L.L
J07BX05 ABRYSVO B RSV subgroup A stabilized perfusion F antigen 60mcg - 60mcg, RSV subgroup B stabilized perfusion F antigen 60mcg - 60mcg, Glycoprotein F stabilized in the perfusion conformation - Injectable powder + solvent 22,650,721 L.L
D10BA01 ABSORICA LIDOSE G Isotretinoin - 16mg 16mg Capsule, hard 1,827,045 L.L
N02AB03 ABSTRAL B Fentanyl (citrate) - 200mcg 200mcg Tablet 5,261,143 L.L
N02AB03 ABSTRAL B Fentanyl (citrate) - 100mcg 100mcg Tablet 3,419,743 L.L
N07BB03 ACAMPROSATE BIOGARAN G Acamprosate - 333mg 333mg Tablet, gastroresistant 3,641,813 L.L
V01AA ACARIZAX 12 SQ-HDM ORAL LYOPHILISATE B Allergen extracts - 12 SQ-HDM Tablet, lyophilised 9,366,451 L.L
R05CB01 ACC LONG G N-acetylcysteine - 600mg, Vitamin C - 75mg 600mg Tablet, effervescent 286,238 L.L
C07AB04 ACEBUTOLOL BIOGARAN G Acebutolol HCl - 400mg 400mg Tablet, coated 615,480 L.L
C07AB04 ACEBUTOLOL BIOGARAN G Acebutolol HCl - 200mg 200mg Tablet, coated 464,970 L.L
M01AB16 ACECLOFAR G Aceclofenac - 100mg 100mg Tablet 131,697 L.L
S01EC01 ACETAZOLAMIDE G Acetazolamide - 250mg 250mg Tablet 1,001,163 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026